Does ENHANCE diminish confidence in lowering LDL or in ezetimibe?
Does ENHANCE diminish confidence in lowering LDL or in ezetimibe?
复制标题
DOI：
10.1056/nejme0801608
复制
发表时间：
2008-04
期刊：
影响因子：
--
通讯作者：
B. Brown;Allen J. Taylor
中科院分区：
文献类型：
--
作者：
B. Brown;Allen J. Taylor
在本期杂志中，Kastelein等1报道了一项为期2年的研究结果，比较了每日80 mg辛伐他汀加安慰剂或10 mg依折麦布治疗对家族性高胆固醇血症患者颈动脉内膜中层厚度平均变化的影响。这项研究被称为依折麦布和辛伐他汀在高胆固醇血症中增强动脉粥样硬化消退（ENHANCE）试验，尽管低密度脂蛋白（LDL）胆固醇水平的组间差异为51 mg，但在内膜中层厚度（血管疾病的常用风险替代品）或临床结果方面的几个终点中的任何一个方面均无显著性组间差异。. .
In this issue of the Journal, Kastelein et al.1 report the results of a 2-year study comparing daily therapy with 80 mg of simvastatin plus either placebo or 10 mg of ezetimibe on the average change in carotid intima–media thickness in patients with familial hypercholesterolemia. The study, called the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial, showed no significant between-group differences in any of several end points with respect to intima–media thickness (a commonly used risk surrogate for vascular disease) or clinical results, despite a between-group difference in levels of low-density lipoprotein (LDL) cholesterol of 51 mg . . .